Current findings elucidating the role of IL-6 in breast cancer progression, metastasis, and anti-cancer immunity, suggest the IL-6/JAK/STAT3 signaling pathway is an actionable target with preclinical and clinical studies demonstrating therapeutic potential in both primary and metastatic breast cancer. The gene discussed is STAT3; the disease is cancer.